United States: Learnings From The FDA Hearing On Cannabis And Cannabis-Derived Compounds

On Friday May 31, 2019, the Food and Drug Administration (FDA) held a public hearing on the topic of cannabis or cannabis-derived compounds. The FDA held the hearing to gather information regarding the safety risks and health benefits associated with cannabis products. More than 110 speakers, including academic researchers, trade associations and cannabis product manufacturers, presented to the FDA panel during the all-day hearing. Below we outline the notable points from the hearing, including statements by FDA officials and interesting speaker comments.

This hearing must be viewed as part of the FDA's information-gathering process. The agency made no pronouncements regarding its regulatory approach toward cannabis and cannabis-derived compounds. In announcing this hearing in early April, former Commissioner Scott Gottlieb cautioned that the questions surrounding possible legal pathways for cannabidiol (CBD) and other cannabis-derived compounds will take time to resolve fully. Furthermore, the FDA will accept submissions to the public docket associated with the hearing until July 2, 2019. We do not expect FDA to make any pronouncements prior to considering all this information.

A. Opening Remarks by Acting Commissioner Ned Sharpless

1) The FDA's role in regulating cannabis and cannabis-derived products is not new.

  1. Cannabis contains many biological compounds, including tetrahydrocannabinol (THC) and CBD.
  2. Adding such compounds to a food product or cosmetic, or marketing these compounds as a drug or dietary supplement, clearly falls under the FDA's jurisdiction.

2) There have been recent shifts in the laws regarding cannabis.

  1. An increasing number of states have legalized cannabis for medical and/or recreational use.
  2. The 2018 Farm Bill removed hemp (with less than 0.3% THC) from the Controlled Substance Act's definition of "marihuana."

3) The 2018 Farm Bill explicitly preserved the FDA's regulatory authority, and therefore the normal FDA processes apply, depending on whether a product enters the market as a food, drug or dietary supplement.

  1. New drugs with cannabis or cannabis-derived products must get preapproval.
    1. For example, the FDA recently approved Epidiolex, a drug containing CBD that treats pediatric epilepsy.
      1. "It is critical that we continue to do what we can to support the science needed to develop new drugs from cannabis."
  2. Food additives must generally be approved or be Generally Recognized as Safe (GRAS).
    1. The FDA recently evaluated three GRAS notices for hemp seed ingredients and had no objections. Thus, these ingredients can lawfully be added to food.
  3. Because cannabis-derived products such as CBD have been approved as drugs—see, e.g., Epidiolex—the Federal Food Drug and Cosmetic Act (FDCA) provides an additional barrier in adding such products to foods and dietary supplements.
    1. The FDA takes the position that the statute's exception for substances marketed as food and/or dietary supplements before clinical trials began for an approved drug does not apply in this case.
    2. Further, although the FDCA explicitly authorizes the FDA to issue regulations to create exceptions to the above rule, Acting Commissioner Sharpless emphasized that the FDA has never acted under this authority and, thus, such action would be "new terrain."

4) The FDA knows little about the health risks associated with CBD and other cannabis-derived products.

  1. The agency needs to see additional research specifically focusing on CBD.

5) The FDA is aware that many companies currently market cannabis products in violation of federal law.

  1. The FDA's chief concern is that the marketing of such products with unproven, inaccurate and fraudulent health claims places the health and safety of consumers at risk by causing patients to forego effective and necessary medical treatment.
  2. Moreover, the FDA does not have a policy of enforcement discretion with respect to any CBD products.

B. Repeat Questions and Concerns Expressed by FDA Staff on Panel

1) Availability of Data

  1. FDA panelists routinely asked speakers to submit any data, studies or research to the public record.

2) Possible Dosing Limits

  1. FDA panelists routinely asked speakers about how the FDA could theoretically establish dosing limits. Most of the speakers did not have strong answers to these questions, as cannabis and cannabis-derived compounds affect individuals in different ways based on a multitude of factors.
    1. The panelists were especially interested in how the effects of these products varies by type of ingestion, such as consuming edibles, vaping, smoking and topical applications.
  2. A representative from the American Epilepsy Society expressed concerns over patients using cheaper, "generic" CBD products available on the market as opposed to the more expensive, FDA-approved Epidiolex drug.
    1. When a panelist asked how patients handle dosing for these products, the representative replied that "they make it up as they go along."

3) Preserving Incentives for Drug Research

  1. FDA panelists expressed concerns regarding the possibility that allowing the commercial sale of CBD and other products could affect the incentives for research into the use of cannabis in life-saving drugs.
    1. This question was posed to two separate speakers discussing research into the use of CBD to treat Alzheimer's and Parkinson's.

C. Main Themes

1) Concerns About Fraudulent and Dangerous CBD Products on the Market

  1. Many speakers—including many proponents of CBD legalization—spoke about the vast amount of CBD products on the market making false or misleading claims.
    1. A researcher from Virginia Commonwealth University gave numerous examples of individuals getting sick from mislabeled CBD products and "synthetic" CBD products.
    2. Speakers presented results from testing select CBD products on the market that revealed many of the top-selling products have vastly different amounts of CBD and THC than what the label stated.
  2. Many speakers pushed for greater FDA regulatory leadership to enforce clear labeling rules.

2) Conflicting Ideas on the Extent of Current Data/Research on Safety of CBD

  1. Acting FDA Commissioner Sharpless and many of the academic speakers expressed concerns about the lack of research studies on the effects of CBD.
  2. At the same time, many proponents argued that there was a significant amount of data showing that CBD is generally safe.

3) Regulating Legal Cannabis Would Be No Different than Regulating Any Other Products

  1. Many speakers asserted that the FDA's regulation of cannabis as a food or dietary supplement would be nothing new for the agency.
    1. The FDA can use the New Dietary Ingredients (NDI) notification process.
    2. The FDA can issue regulations ensuring Good Manufacturing Practices (GMPs)

D. Select Examples of Notable Speaker Comments

1) Consumer Health Care Products Association

  1. The association announced support for the status quo for CBD when it comes to medicinal uses, but would like to see a path forward for legal use of CBD in dietary supplements, based on the exception for prior use.
  2. At the same time, the association urged greater FDA enforcement (i.e., more than warning letters) against companies that market unsafe or mislabeled CBD products, citing misleading health benefits.

2) Grocery Manufacturers Association

  1. The trade association representing food, beverage and consumer product companies pressed the FDA for a clear, national legal pathway to sell CBD products and strong FDA regulatory leadership to enhance consumer trust in the safety of these products.

3) Maryland Packaging

  1. The food packaging company's CEO explained that brand-owner clients want the company to manufacture and co-pack products that contain CBD.
  2. The CEO urged the FDA to establish a legal pathway to safely distribute these products, because by not taking action, the FDA encourages black market dealings; and those manufacturing such products take fewer safety precautions and are less likely to follow approved procedures and regulations.
  3. The CEO suggested that the FDA establish a legal path to reward the companies that follow the rules.

4) Food Marketing Institute (FMI)

  1. The food retail industry advocate representing both small and large supermarket chains told the FDA panel that there is mass confusion among client store chains regarding the legality of CBD products. Strong consumer demand is pushing supermarkets to increasingly ask FMI questions about the legality of stocking and selling CBD products.
  2. FMI urged the FDA to establish a legal pathway that would ensure these CBD products are safe and beneficial to consumers.

5) State Officials

  1. Brenda Morris of Florida's Department of Agriculture expressed concerns about the patchwork of state laws and enforcement priorities. Morris explained that this problem will only get worse as many states consider legislation to regulate hemp following the passage of the 2018 Farm Bill.
  2. Joseph Reardon of North Carolina's Department of Agriculture encouraged the FDA to establish a legal pathway for hemp-derived CBD that would aid North Carolina's farmers.

6) Consumer Reports

  1. Consumer Reports presented the results of a telephone survey of more than 4,000 adults.
  2. The survey revealed that:
    1. Many adults use CBD. One out of four adults reported using CBD at least once in last 24 months, and one out of seven use CBD regularly.
    2. A majority of CBD users find it effective. This percentage was especially high for people using CBD to reduce stress and anxiety.
    3. Consumers consider CBD to be safe

7) Noramco

  1. a) The cannabis-derived ingredients manufacturer suggested that 0.1% THC should be the FDA's limit for its use in food and/or dietary supplements, as opposed to the 0.3% limit in the 2018 Farm Bill.

8) Natural Products Association (NPA)

  1. The largest trade organization representing the dietary supplements and natural products industry urged the FDA to establish a safe harbor for CBD products.
  2. In contrast to what Acting Commissioner Sharpless stated in his prepared remarks, NPA argued that issuing a regulation to authorize CBD products would not be new ground for the FDA. A similar precedent was established for red yeast rice, where FDA distinguished between traditional red yeast rice and red yeast rice artificially manipulated.

9) Council for Responsible Nutrition (CRN)

  1. Another trade association for the dietary supplement industry argued that the FDCA provision preventing the addition of FDA-approved drugs in food and dietary supplements is not focused on safety concerns, but rather on commercial incentives to discover and market new drugs.
  2. CRN encouraged the FDA to address first the issue of whether CBD is precluded by Section 321(ff)(3)(B) of the FDCA. The section states that a dietary supplement does not include a drug or an article authorized for investigation as a new drug that was not previously marketed as a dietary supplement before addressing how the products should safely enter markets across the separate channels: drug, food or dietary supplement.

10) Community Alliances for Drug Free Youth

  1. The organization strongly urged the FDA to not allow any amounts of THC in consumer products, arguing that there is no research identifying a safe level of THC.
  2. Further, the organization asserted that just like in alcohol and tobacco, age limits would not work.

In short, the public hearing represents an important information-gathering step for the FDA deciding what actions to take in regard to cannabis and cannabis-derived products. As stated above, absent congressional intervention, we do not expect swift or imminent direction from the FDA on potential legal pathways for marketing CBD and other cannabis-derived compounds in foods and dietary supplements.

Learnings From The FDA Hearing On Cannabis And Cannabis-Derived Compounds

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions